Study of bb21217 in Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

bb21217

autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution

Trial Locations (11)

10029

Mount Sinai Medical Center, New York

30322

Winship Cancer Insitute, Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

55905

Mayo Clinic Cancer Center, Rochester

60637

University of Chicago, Chicago

94143

UCSF Medical Center at Parnassus, San Francisco

02144

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

07601

John Theurer Cancer Center at Hackensack UMC, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

2seventy bio

INDUSTRY